A two-arm randomized trial in recurrent GBM patients (NCT02529072) demonstrated that treatment with a DC vaccine in combination with the anti-PD-1 agent nivolumab resulted in prolonged survival compared with single nivolumab treatment (mOS, 15.3 vs. 8.0 months; mPFS, 6.3 vs. 4.3 months). The gene discussed is PDCD1; the disease is glioblastoma.